Haleon plc (NYSE:HLN) Stock Position Lifted by Huntington National Bank

Huntington National Bank grew its position in Haleon plc (NYSE:HLNFree Report) by 7.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,084 shares of the company’s stock after acquiring an additional 2,568 shares during the quarter. Huntington National Bank’s holdings in Haleon were worth $414,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Manning & Napier Advisors LLC bought a new stake in Haleon during the second quarter valued at $2,833,000. Sei Investments Co. raised its stake in Haleon by 79.1% during the first quarter. Sei Investments Co. now owns 781,089 shares of the company’s stock worth $6,632,000 after acquiring an additional 345,036 shares during the period. Magnetar Financial LLC acquired a new stake in Haleon during the first quarter worth about $853,000. Cetera Advisors LLC lifted its holdings in Haleon by 524.3% in the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock worth $696,000 after acquiring an additional 68,857 shares during the last quarter. Finally, Cetera Investment Advisers boosted its stake in Haleon by 106.3% in the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock valued at $1,985,000 after acquiring an additional 120,447 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on HLN. The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. UBS Group upgraded Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley upped their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, Berenberg Bank started coverage on shares of Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $10.95.

View Our Latest Research Report on HLN

Haleon Price Performance

Shares of NYSE HLN opened at $9.39 on Friday. The firm’s 50-day simple moving average is $10.10 and its 200 day simple moving average is $9.34. The stock has a market cap of $42.51 billion, a P/E ratio of 27.62, a P/E/G ratio of 2.79 and a beta of 0.30. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80.

Haleon Profile

(Free Report)

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

Featured Stories

Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon plc (NYSE:HLNFree Report).

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.